SCREENING MODULE Clause Samples

SCREENING MODULE. In the first module of the Research (the "SCREENING MODULE"), CombinatoRx shall screen a library of approximately 500 drug compounds in order to identify promising combination drugs for the potential treatment of SMA. The parties agree that the screening library will consist of drug molecules which are known to be able to cross the human blood-brain barrier. As promptly as practicable following the Effective Date, the parties shall work together to define the screening library for the Screening Module. For such screening, CombinatoRx shall use a fibroblast SMN protein induction assay optimized for combination high-throughput screening by CombinatoRx. CombinatoRx shall disclose the results of such screening to the Foundation in accordance with Section 2.6, and the parties shall consult with each other to select one or more combination drug candidates meeting the criteria set forth in the Research Plan (or otherwise mutually agreed upon by the parties) for further
View Source
SCREENING MODULE. For conduct of the Screening Module, the Foundation shall pay the following amounts to CombinatoRx upon occurrence of the applicable event specified below: (i) Within 10 days of the Effective Date, the Foundation will pay to CombinatoRx US$190,000; (ii) Within 30 days of the Foundation's receipt of the Research Report for the first quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000; (iii) Within 30 days of the Foundation's receipt of the Research Report for the second quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000; (iv) Within 30 days of the Foundation's receipt of the Research Report for the third quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000; (v) Within 30 days of the Foundation's receipt of the Research Report for the fourth quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000; and (vi) Within 30 days of the Foundation's receipt of the Research Report for the fifth quarter of the Research Term, the Foundation will pay to CombinatoRx US$190,000;
View Source

Related to SCREENING MODULE

  • RE-WEIGHING PRODUCT Deliveries are subject to re- weighing at the point of destination by the Authorized User. If shrinkage occurs which exceeds that normally allowable in the trade, the Authorized User shall have the option to require delivery of the difference in quantity or to reduce the payment accordingly. Such option shall be exercised in writing by the Authorized User.

  • Laboratory Testing All laboratories selected by UPS Freight for analyzing Controlled Substances Testing will be HHS certified.

  • Random Drug Testing All employees covered by this Agreement shall be subject to random drug testing in accordance with Appendix D.

  • Target Population TREATMENT FOR ADULT (TRA) Target Population

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.